Benjamin G. Challis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Benjamin G. Challis has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Agneta Holmäng
Institute of Neuroscience and Physiology, Department of Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
2 shared publications David Baker
2 shared publications- Dimitrios Vitsios
Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
2 shared publications - Heaseung Sophia Chung
Dynamic Omics, Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA
2 shared publications - Kristina Wallenius
Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
2 shared publications - Lawrence Middleton
Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 10 February 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (3)
Longitudinal clinical and proteomic diabetes signatures in women with a history of gestational diabetes
- 10 February 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (3)
Open AccessLongitudinal clinical and proteomic diabetes signatures in women with a history of gestational diabetes
- Open Access
- 26 November 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (2)
Longitudinal clinical and proteomic diabetes signatures in women with a history of gestational diabetes
We characterized the longitudinal serum protein signatures of women 6 and 10 years after having gestational diabetes mellitus (GDM) to identify factors associated with the development of type 2 diabetes mellitus (T2D) and prediabetes in this at-risk post-GDM population, aiming to discover potential biomarkers for early diagnosis and prevention of T2D. Our study identified 75 T2D-associated serum proteins and 23 prediabetes-associated proteins, some of which were validated in an independent T2D cohort. Machine learning (ML) performed on the longitudinal proteomics highlighted protein signatures associated with progression to post-GDM diabetes. We also proposed prognostic biomarker candidates that were differentially regulated in healthy participants at 6 years postpartum who later progressed to having T2D. Our longitudinal study revealed T2D risk factors for post-GDM populations who are relatively young and healthy, providing insights for clinical decisions and early lifestyle interventions.
- 26 November 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (2)
Open AccessLongitudinal clinical and proteomic diabetes signatures in women with a history of gestational diabetes
We characterized the longitudinal serum protein signatures of women 6 and 10 years after having gestational diabetes mellitus (GDM) to identify factors associated with the development of type 2 diabetes mellitus (T2D) and prediabetes in this at-risk post-GDM population, aiming to discover potential biomarkers for early diagnosis and prevention of T2D. Our study identified 75 T2D-associated serum proteins and 23 prediabetes-associated proteins, some of which were validated in an independent T2D cohort. Machine learning (ML) performed on the longitudinal proteomics highlighted protein signatures associated with progression to post-GDM diabetes. We also proposed prognostic biomarker candidates that were differentially regulated in healthy participants at 6 years postpartum who later progressed to having T2D. Our longitudinal study revealed T2D risk factors for post-GDM populations who are relatively young and healthy, providing insights for clinical decisions and early lifestyle interventions.